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Objectives The purpose of this study was to assess the pathological responses of atherosclerotic
saphenous vein bypass grafts (SVBGs) to drug-eluting stents (DES) versus bare-metal stents (BMS).
Background Repeat bypass surgery is typically associated with a high rate of morbidity and mortal-
ity. Percutaneous coronary interventions have emerged as the preferred treatment; however, only
limited data are available on SVBGs pathological responses to DES and BMS.
Methods Formalin-ﬁxed SVBG of 2 years duration (n  31) were collected to histologically charac-
terize advanced atherosclerotic lesions in native SVBG. In a separate group, SVBGs treated with DES
(n  9) and BMS (n  9) for 30 days duration were assessed for morphological and morphometric
changes.
Results Necrotic core lesions were identiﬁed in 25% of SVBG sections, and plaque rupture with lu-
minal thrombosis was observed in 6.3% of histological sections (32% [10 of 31] vein grafts exam-
ined). Morphometry of DES demonstrated reduction in neointimal thickening versus BMS (0.13 mm
[interquartile range: 0.06 to 0.16 mm] vs. 0.30 mm [interquartile range: 0.20 to 0.48 mm], p  0.004).
DES lesions also showed greater delayed healing characterized by increased peristrut ﬁbrin deposi-
tion, higher percentage of uncovered struts, and less endothelialization compared with BMS. Stent
fractures (DES 56% vs. BMS 11%, p  0.045) and late stent thrombosis (DES 44% vs. BMS 0%,
p  0.023) were more common in DES versus BMS.
Conclusions Advanced SVBG atherosclerotic lesions are characterized by large hemorrhagic necrotic
cores. Stenting of such lesions is associated with delayed vascular healing and late thrombosis par-
ticularly following DES implantation, which may help explain the higher rates of cardiovascular
events observed in SVBG stenting as compared with native coronary arteries. (J Am Coll Cardiol
Intv 2012;5:666–74) © 2012 by the American College of Cardiology Foundation
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667Saphenous vein bypass grafts (SVBGs) remain the most
frequently used conduits for coronary artery bypass graft
(CABG) surgery. These grafts are susceptible to the rapid
development of atherosclerotic lesions, and repeat revascu-
larization procedures are common after 5 years (1,2). Since
repeat CABG surgery is associated with increased morbidity
and mortality compared with the index bypass procedure,
percutaneous coronary intervention has emerged as the
preferred treatment for atherosclerotic SVBG failure (3–6).
Bare-metal stent (BMS) implantation in SVBG was shown
to reduce clinical events as compared with balloon angio-
plasty (7,8). However, results of BMS implantation in
SVBGs are less favorable than those in native coronary
arteries, with restenosis rates exceeding 30%, and are asso-
ciated with a high rate of major cardiovascular events (9).
Reduced restenosis rates associated with sirolimus (SES)
(Cypher, Cordis, Johnson & Johnson, Miami, Florida) and
paclitaxel (PES) (Taxus, Boston Scientific Corporation, Boston,
Massachusetts) drug-eluting stents in native coronary arteries
has resulted in the frequent use of drug-eluting stents
(DES) in atherosclerotic SVBGs (10,11). Within 1 year
post-procedure, DES implantation in SVBGs result in a
reduction in target lesion revascularization rates compared
with BMS (DES: 4% vs. BMS: 11%, p  0.22) (12);
however, the long-term effectiveness of this benefit of DES
versus BMS has been inconsistent (13). In a randomized
controlled trial of SVBG revascularization, DES had a
lower incidence of target vessel revascularization at 6
months (DES: 4.3% vs. BMS: 24.5%, p 0.005), but target
essel revascularization rates were not significantly different
t 2 years (DES: 36% vs. BMS: 41%, p  0.64) (14–16).
Preclinical and human autopsy studies have shown that
ES implanted in native coronary arteries are associated
ith delayed arterial healing compared with BMS (17).
owever, pathological studies of atherosclerotic SVBGs
reated with DES versus BMS are lacking, and it is
oteworthy that the atherosclerotic process is highly accel-
rated and has some morphological differences compared
ith native coronary disease.
The objectives of this study were to perform a detailed
athological assessment of advanced SVBG atherosclerotic
laques and to determine the vascular healing profile of
VBGs implanted with SES or PES of 30 days implant
uration to gain insights into the safety and effectiveness of
ES implantation.
ethods
SVBG atherosclerotic plaque assessment. Formalin-fixed
human hearts from patients treated with CABG surgery at
least 2 years before death were selected from our CVPath
database. SVBGs were excised in their entirety, serially
sectioned transversely at 3-mm intervals, and then embed-ded in paraffin. Each 5-m section was stained with
hematoxylin and eosin and Movat pentachrome stains.
The SVBG cross sections were categorized as nonathero-
sclerotic (i.e., only fibrointimal hyperplasia present [fibro-
intimal proliferation (FIT)]) or atherosclerotic. Atheroscle-
rotic SVBG lesions were further categorized as: 1) intimal
xanthoma or fatty streak lesions (foam cell accumulation
lacking a fibrous cap or lipid core); 2) fibroatheroma (FA)
lesions (plaques with well-defined necrotic cores with or
without focal accumulations of foam cells); 3) hemorrhagic
necrotic core (HNC) lesions with intact fibrous caps; and
4) plaque rupture with a disrupted cap and an overlying
thrombus. Morphometric analysis was used to measure the
area within the internal elastic lamina, lumen, total plaque
area, and total necrotic core area and to calculate area
stenosis and the percentage of the plaque occupied by a
necrotic core (18,19).
Stented SVBGs. From our regis-
try of 600 human coronary
artery stents submitted for con-
sultation, SVBGs stented with
DES implanted30 days before
death were identified. Clinical
histories and cardiac catheteriza-
tion reports were reviewed when
available. The control group
consisted of SVBGs treated with
BMS with matched stent
lengths and implant durations.
Stented segments of SVBGs
were fixed in 10% buffered for-
malin, dissected off the heart,
radiographed, and processed for
plastic embedding. Stented vein
grafts were sawed consecutively
from the proximal to distal ends
of the stents at 2- to 3-mm
intervals. The sections were cut at 6 m and stained with
hematoxylin and eosin and Movat pentachrome stains.
Acute luminal thrombus was defined as a platelet-rich
thrombus that occupied 30% of the cross-sectional area of
the lumen, and restenosis was defined as 75% in-stent
cross-sectional area luminal narrowing by neointima. Pre-
mortem luminal thrombus was distinguished from post-
mortem thrombus based on histological appearance as
pre-mortem thrombus is composed of platelet aggregation
without white cells, and a propagated thrombus is composed
of an interspersed layer of fibrin and red cells, whereas a
post-mortem thrombus lacks the layered appearance. Late
stent thrombosis, consistent with the clinical definition, was
defined as thrombosis within a stent implanted 30 days
before death (20). The cause of death was determined after
complete autopsy and was categorized as stent-related,
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft
DES  drug-eluting stent(s)
FA  fibroatheroma(s)
FIT  fibrointimal
proliferation
HNC  hemorrhagic necrotic
core
IQR  interquartile range
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
SVBG  saphenous vein
bypass graftnon–stent-related cardiac, and noncardiac (21).
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668Computer-guided morphometric measurements and his-
tological characterization of the stented segments, including
fibrin, inflammation, strut coverage, strut malapposition,
necrotic core strut penetration, neoatherosclerosis, has been
previously defined (17,21–23).
Statistical analysis. Continuous variables with normal dis-
ribution were expressed as mean  SD. Discrete variables
nd continuous variables with non-normal distribution were
xpressed as median (interquartile range [IQR]). Compar-
sons of continuous variables with normal distribution were
ested by analysis of variance. A Wilcoxon rank sum test was
sed to compare non-normally distributed parameters or
iscrete variables, and the Pearson chi-square test was used for
ategorical variables. Normality of distribution was tested with the
ilk-Shapiro test. A value of p 0.05 was considered statistically
ignificant.
esults
SVBG atherosclerotic plaque assessment. A total of 589
istological cross sections from 31 SVBGs (nonstent-
reated) from 16 patients were prepared and examined.
here were 7 cardiac deaths (4 sudden cardiac deaths) and
noncardiac deaths. CABG surgery had been performed
.5  5.9 years before death (range: 2 to 22 years). Grossly,
older vein grafts (5 years) showed atherosclerotic change
(yellow, with cheesy material and hemorrhage), whereas
those implanted for 2 to 5 years usually showed intimal
thickening with or without foam cell infiltration and ab-
sence of necrotic core. As shown in Table 1, incidence of
fibrointimal thickening was observed in most lesions
(90.3%). Intimal xanthoma and FA with necrotic core were
observed in 74.2% and 64.5% of the 31 SVBGs, respec-
tively. Seventeen of the 31 lesions (54.8%) demonstrated
HNCs, with only 10 lesions (32.3%) showing plaque
rupture.
To further characterize these histological changes, histo-
logical cross sections from all 31 SVBGs (n  589 sections)
were categorized. The results demonstrated that most sec-
tions (56.5%) showed FIT, with the remaining cross sec-
tions (43.5%) demonstrating atherosclerotic changes. Inti-
mal xanthoma was identified in 18.8% of the total SVBG
Table 1. Lesion Morphology, Stenosis, and Lipid Core Size of SVBG (>2 Ye
Changes in SVBG
Incidence per
Lesion (%)
Number of
Sections (%)
FIT 28 (90.3) 333 (56.5) 10
IX 23 (74.2) 111 (18.8) 12
FA with necrotic core 20 (64.5) 70 (11.9) 14
HNC 17 (54.8) 44 (7.5) 1
PR 10 (32.3) 31 (6.3) 1
Values are n (%) or mean SD.FA fibroatheroma; FIT fibrointimal thickening; HNC hemorrhagic necrotic core; IEL internal elasections, followed by lesser incidences of necrotic core
(11.9%), HNCs (7.5%), and plaque rupture and luminal
thrombus (6.3%) (Table 1, Fig. 1). Ruptured plaque was
primarily composed of a disrupted fibrous cap with lipid-
laden macrophages close to underlying necrotic core and
within the fibrous cap. The necrotic core was usually large
with numerous cholesterol clefts and hemorrhage, with the
occasional presence of focal calcification, usually close to the
vein wall (Online Fig. 1). The cap was more discontinuous
than what is seen in native coronary artery disease. The
necrotic core always showed a base of neointimal layer
composed of smooth muscle cells and collagenous matrix.
The fibrous caps of plaque ruptures were significantly
thinner compared with SVBGs with plaque hemorrhage
(82  42 m vs. 214  162 m, respectively, p  0.002).
The mean longitudinal length of plaque ruptures (estimated
by the number of contiguous SVBG cross sections
demonstrating rupture) was 6.6  7.2 mm (range 3.0 to
0 mm).
At the aortic anastomosis, 67% of sites showed only
brointimal proliferation, and 33% had atherosclerotic
laque (with or without lipid core formation). At the distal
nastomosis of SVBG to the native coronary artery, only 4%
emonstrated atherosclerotic plaque, and 96% showed fi-
rointimal thickening.
Stented SVBGs. Eighteen stented SVBGs, including 9 DES
from 7 patients and 9 BMS from 8 patients, were analyzed,
with a mean patient age of 71  10 years and 67  6 years,
respectively. The DES stents consisted of 6 PES and 3 SES.
Implanted BMS were 5 Multi-Link (Abbott Vascular,
Santa Clara, California), 2 AVE (Medtronic, Minneapolis,
Minnesota), 1 Bx Velocity (Cordis Corp, Johnson & John-
son, Warren, New Jersey), and 1 Palmaz-Schatz (Johnson
& Johnson). The duration of stent implantation and stent
length were greater in DES versus BMS, but differences did
not reach statistical significance (Table 2).
Post-mortem radiographs demonstrated fractures in 5 (3
SES and 2 PES) of the 9 DES and in 1 of 9 BMS (Bx
Velocity). Stent fractures ranged from grade II (multiple
breaks with preserved alignment) to grade IV (multiple
breaks with transection but without gap) (24). Most of the
ea
)
Stenosis
(%)
Lipid Core Area
(mm2) % Lipid Core
2.28 34 15 — —
3.02 37 9 — —
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669fractures in the Cypher stents and in the Bx Velocity BMS
(which has the identical platform as the Cypher) were
located in the flexible N-shaped, undulating longitudinal
intersinusoidal-ring linker segments, whereas in Taxus
stents, factures were observed in the straight longitudinal
intercrown linker.
Figure 1. Progression of Atherosclerotic Disease in SVBGs
(A) Within the ﬁrst year, arterialization and ﬁbrointimal thickening of the vein
tima. (C) Between the ﬁrst and third year, formation of a lipid core is observed
lumen narrowing is observed. (E) At 5 to 10 years, plaque rupture of a large n
At the coronary anastomosis, ﬁbrointimal growth is commonly observed, wher
Table 2. Patient and Lesion Characteristics of DES- and BMS-Treated
SVBG (>30 Days)
DES (n  9) BMS (n  9) p Value
Age, yrs 7110 676 0.34
Male 6 (66) 7 (78) 0.62
SVBG duration, yrs 8.0 (6.5–10.0) 9.0 (7.0–12.0) 0.53
Stent duration, days 360 (110–720) 360 (360–900) 0.39
Underlying SVBG disease
FIT 4 (44) 5 (56) 0.57
FA 1 (11) 0 (0)
FA with HNC 4 (44) 4 (44)
Cypher/Taxus 3/6 — —
Stents 2 (1–2) 1 (1–1) 0.13
Stent length, mm 20.0 (14.0–47.5) 13.0 (11.0–26.5) 0.12
Stent fracture 5 (56) 1 (11) 0.045
Thrombosis 4 (44) 0 (0) 0.023
Restenosis 0 (0) 3 (33) 0.058
Malapposition 2 (22) 0 (0) 0.13
Strut NC penetration 4 (44) 4 (44) 0.49
Cause of death
Stent related 4 (44) 3 (33) 0.38
Non–stent-related cardiac 4 (44) 4 (44)
Noncardiac 1 (11) 2 (22)
Values are mean SD, n (%), and median (interquartile range).
BMS  bare-metal stent(s); DES  drug-eluting stent(s); NC  necrotic core; other abbrevia-tions as in Table 1.Morphometric analysis of stented lesions. Lumen, stent, and
plaque area measurements were comparable between the
BMS and DES groups. Mean neointimal thickness (0.30
mm [IQR: 0.20 to 0.48 mm] versus 0.13 mm [IQR: 0.06 to
0.16 mm], p  0.004), neointimal area (4.90  2.20 mm2
vs. 2.00  0.87 mm2, p  0.002], and percent area stenosis
(47.9  20.5% vs. 30.1  12.4%, p  0.041) were
ignificantly greater in BMS than in DES, respectively
Table 3).
Histological observations. A total of 216 sections of stented
VBGs were examined with 12  3 stent struts per section
or a total of 785 struts. The underlying lesion characteristic
f the stented vein grafts ranged from FIT, FA with a
ecrotic core, and FA with HNC, with similar distributions
etween DES and BMS cases (Online Tables 1 and 2). In
ES, fibrin was observed at later time points and was
bserved more frequently around stent struts as compared
ith BMS; fibrin was interspersed with inflammatory cells
nd/or surrounded by smooth muscle cells and proteogly-
an/collagen matrix (Table 3). The percentage of struts
ssociated with inflammatory cells (eosinophils, lympho-
ytes, and foreign-body giant cells) was similar between the
ES and BMS. Luminal neutrophil and eosinophil foci
ere numerically greater in DES versus BMS, but the
ifferences were not statistically significant (Table 3). Dis-
uption of lipid core by stent struts was observed in all
tented SVBG atherosclerotic lesions (DES and BMS ) in
hich an underlying FA was present, except in 1 lesion
here a thick fibrous cap of700 m was seen. Figures 2 and 3
illustrate necrotic core strut penetration of DES and BMS,
respectively. The frequency of stent strut penetration into
s observed. (B) This is followed by foam cell accumulation within the neoin-
After 4 to 5 years, hemorrhage into the lipid core and moderate-to-severe
c core accompanied with hemorrhage often leads to luminal thrombus. (F)
herosclerosis is uncommon. SVBG  saphenous vein bypass graft.graft i
. (D)
ecrotipre-existing lipid core was similar between stent groups.
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670Uncovered struts were more common in DES compared
with BMS, and endothelialization of DES SVBGs was
significantly less frequent compared with BMS (Table 3).
For stents implanted 360 days, uncovered struts were
more frequently observed in samples with strut necrotic core
penetration, with greater frequency in DES as compared
with BMS, whereas stents without strut necrotic core
penetration, irrespective of stent type, were more likely to be
covered (Online Tables 1 and 2).
Evidence of accelerated in-stent atherosclerotic change
within the neointima was present with equal frequency in
BMS (3 of 9 lesions) and DES (4 out of 9 lesions), and was
observed at 360 days post-implant (Fig. 4). Malapposition
of stent struts was only observed in DES SVBGs (2 of 9
lesions, both PES). The percentage of struts associated with
calcification was similar between BMS and DES (Table 3).
Discussion
The present study demonstrates that flow-limiting SVBG
plaques are characterized by FA with large necrotic cores
and are frequently accompanied by plaque hemorrhage and
a disrupted fibrous cap. In the treatment of diseased SVBG,
DES reduced neointimal thickness as compared with BMS,
but this benefit was associated with delayed healing char-
acterized by persistent fibrin deposition, uncovered stent
struts, and incomplete endothelialization. Focal stent strut
penetration into lipid core was common and independent of
BMS or DES stent type, and resulted in long-term (360
days) uncovered struts with greater frequency in DES as
Table 3. Pathological and Morphometric Comparison of
DES- and BMS-Stented SVBG
DES (n  9) BMS (n  9) p Value
Lumen area, mm2 5.57 3.20 6.33 3.85 0.65
Stent area, mm2 6.7 (5.4–9.4) 11.1 (6.0–15.5) 0.15
Outer vein area, mm2 15.23 6.63 19.13 9.42 0.32
NC area, mm2* 2.7 (1.3–4.0) 2.5 (1.0–4.0) 0.95
Plaque area, mm2 7.67 3.29 7.91 4.97 0.91
Neointimal area, mm2 2.00 0.87 4.90 2.20 0.002
Stenosis, % 30.05 12.44 47.86 20.54 0.041
Struts with inﬂammation, % 20.0 (11.9–54.0) 16.1 (10.1–27.8) 0.72
Struts with calciﬁcation, % 6.7 (0–38.0) 17.6 (0–30.5) 0.96
Struts penetrating NC, %* 9.8 (1.7–19.1) 13.0 (4.1–30.5) 0.25
Mean no. of
neutrophils/eosinophils
21.6 (6.3–43.0) 7.0 (4.0–34.5) 0.34
Neointimal thickness, mm 0.13 (0.06–0.16) 0.30 (0.20–0.48) 0.004
Struts with ﬁbrin, % 81.2 (58.3–92.8) 50.0 (30.5–63.9) 0.019
Uncovered struts, % 19.6 (3.3–55.2) 5.1 (0.0–7.3) 0.043
Endothelialization, % 70.0 (60.6–92.5) 98.3 (89.2–100) 0.028
Values are mean SD or median interquartile range. p values in bold are statistically significant.
*Only performed in lesions with necrotic core.
Abbreviations as in Tables 1 and 2.compared with BMS. Late stent thrombosis was seen more cfrequently in SVBG DES (4 of 9 lesions) versus BMS (0 of
9 lesions), which was almost exclusively seen in vein grafts
with underlying large HNCs. Taken together, these find-
ings suggest the long-term increase in delayed healing of
DES stents implanted in SVBG is related to the severity of
the underlying disease and uncovered struts, which result in
late stent thrombosis.
Vein graft disease. Compared with native coronary arteries,
VBGs undergo more rapid atherosclerotic lesion develop-
ent. Reported rates of vein bypass graft occlusion is 8%
arly after the operation, 13% at 1 year, 20% at 5 years, 41%
t 10 years, and 45% at more than 11.5 years (4,25). Our
aboratory and others have shown that within the first year
ollowing SVBG implantation, the vein wall is thickened by
he neointimal growth, which has been postulated to occur
ecause of the veins being exposed to arterial pressure that
s 10-fold higher than venous pressure. This hemodynamic
oad leads to increased levels of intracellular adhesion molecule
ICAM)-1, vascular adhesion molecule (VCAM)-1, and
onocyte chemotactic protein (MCP)-1 (26). In animal
odels, the magnitude of shear stress across the endothelial
urface of vein grafts has been shown to be inversely
roportional to neointimal growth, suggesting that the
ifference in flow rates between arterial and venous beds
lays an important role in the progression of vein graft
isease (27).
Over time, the SVBG neointima is infiltrated by macro-
hages, with varying degrees of apoptosis and necrotic core
ormation (28). Compared with native coronary artery
isease, SVBG atherosclerotic lesions are more often con-
entric and diffuse, with a less well-defined fibrous cap,
hich is more vulnerable to rupture and thrombosis (29).
he present study demonstrates a high frequency of plaque
upture (32%, 10 of 31 SVBG) of a thin fibrous cap in
esions containing large HNCs. It is likely that implantation
f stents in SVBGs with thin fibrous caps and a large HNC
s an important factor in the healing of DES and BMS.
Delayed vein graft healing after DES. The impact of DES on
aphenous vein graft healing is poorly understood. From
uman native coronary arterial autopsy studies, DES have
een shown to effectively suppress smooth muscle cell
roliferation, followed by prolonged fibrin deposition and
ncomplete endothelialization in noncomplex lesions ob-
erved up to 12 months post-DES implantation. By con-
rast, endothelialization is nearly complete by 3 to 4 months
ost-BMS placement (30). In the present study, the fre-
uency of uncovered stent struts and fibrin deposition was
ignificantly higher is SVBGs stented with DES compared
ith BMS, which is similar to observations in native
oronary arteries (17).
In comparing the histopathology of DES in SVBG (in
he presence of a necrotic core) to native coronary arteries,
here was a similar incidence of strut penetration of necrotic
ore and the number of uncovered struts (22). However, a
f thro
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671greater incidence of fibrin was observed in SVBG stented
with DES as compared with native arteries in patients
presenting with acute coronary syndrome. There was also
greater delayed healing in SVBG than in native coronary
arteries, likely because of greater delay in endothelialization
of vein graft disease. Because the number of cases with DES
in SVBG was far too few, it is difficult to compare patients
presenting with acute myocardial infarction in SVBG versus
native coronaries. However, we suspect that there would be
greater delayed healing and early neoatherosclerotic change
in vein grafts than in native coronary disease.
The data also demonstrate the adverse effects of stent
struts within a necrotic core on stent healing. In DES
samples implanted for 360 days with necrotic core pene-
tration, greater incidence of uncovered struts was observed
in comparison with DES without strut necrotic core pene-
tration, where nearly all struts were completely covered. As
the presence of uncovered struts highly correlates with
endothelialization, neointimal coverage of stent struts could
be used as a surrogate marker for endothelialization. Un-
doubtedly these results correlate directly to the underlying
disease in SVBG, as strut necrotic core penetration was only
observed in grafts with large HNCs. This pattern was
Figure 2. Histological Evidence of Delayed Healing and NC Strut Penetratio
An 84-year-old women received 2 overlapping paclitaxel-eluting Taxus stents i
lipid-rich necrotic core (NC) region. The image of the stents at the top shows
box in each panel indicates the location of the enlarged images a, b, and c (
rupted by the stent struts (asterisks). (B) In the overlapping region, struts are
posed of ﬁbrin. (C) In the distal region, struts are surrounded by a thin layer oobserved both for BMS and DES with incidence of necroticcore penetration being similar; nevertheless, the number of
uncovered struts was much greater in DES as compared
with BMS (Online Tables 1 and 2).
Atherosclerotic change was observed following stenting
of SVBG in DES as well as BMS, and this change occurred
as early as 360 days. These findings are similar to those
previously reported by Depre et al. (31) and dissimilar to
those of van Beusekom et al. (32). These differences are
most likely related to overinterpretation of atherosclerotic
change by van Beusekom et al. at early time points (3 to 7
months) and likely represented native vein graft atheroscle-
rotic disease, as suggested by the authors in their discussion.
By contrast, in the study by Depre et al., atherosclerotic
change was observed in 3 of the 12 stent grafts (25%), and
the duration of stent implant was 15, 24, and 24 months,
which is similar to our data showing that the earliest
atherosclerotic change occurred beyond 12 months.
Clinical implications. The present study demonstrates that
DES use for patients with SVBG disease is associated with
a greater incidence of uncovered struts, persistence of fibrin,
and less endothelialization. Because healing is delayed for
long periods (1 year), the safety and efficacy of using DES
cannot be determined by relatively short-term studies.
ES-Treated SVBGs
ted 2 years before death, that demonstrate stent strut penetration into the
cation of the cross sections described in A, B, and C (middle). The yellow
m). (A) The ﬁbrous cap (green arrow, bottom) is shown to have been dis-
ered but are surrounded by a thin layer of thrombus (Thr) primarily com-
mbus. DES  drug-eluting stent(s); SVBG  saphenous vein bypass graft.n in D
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672studies (2 randomized trials and 17 registries) with
follow-up data ranging from 6 to 48 months. Although
most studies with relatively short-term follow up (2 years)
demonstrated a benefit in DES versus BMS (9 of 13
studies), longer-term (2 years) studies were less consistent,
with only 3 of 6 studies showing advantages for DES
implantation. In the only randomized study (RRISC [Re-
duction of Restenosis In Saphenous vein grafts with Cypher
sirolimus-eluting stent] trial) to date, there was a significant
reduction of target lesion revascularization in the DES
group at 6 months versus BMS (5% vs. 22%, p  0.047),
ut this benefit was lost at 3-year follow-up (24% vs. 30%,
 0.55) (14,15). Similarly, Gioia et al. (34) demonstrated
marginal benefit in major adverse cardiac event rates for
ES at 1 year (10% vs. 16%, p  0.15); however, major
dverse cardiac event–free survival rates were comparable
etween DES and BMS at 2 years (19% vs. 18%, p  0.9).
These data suggest that late in-stent neointimal growth
“catch-up” occurs beyond 2 years in SVBGs treated with
DES. Catch-up has been shown in native coronary arteries;
Figure 3. Stent Strut Penetration of Lipid-Rich NC Lesions
A 79-year-old woman received a bare-metal Multi-Link Vision stent 2 years bef
lipid-rich necrotic core (NC). The image of the stent at the top shows the loca
panel indicates the location of the enlarged images a and b (bottom). (A) A t
(B) In the distal region, all struts are shown to be covered by neointima withrates of target vessel revascularization increase for both PES(Taxus) and SES (Cypher) from 1 to 5 years post-stent
implantation (35). In pathological studies of human post-
mortem stented coronary arteries, our laboratory demon-
strated a significant increase in neointimal thickness beyond 18
months in SES and PES (36). In the current study, because of
the small number of specimens examined, it is not possible to
show late catch-up in SVBG. Prospective, randomized long-
term studies will be needed to further define the risk-benefit
profile of DES implantation in SVBGs.
Study limitations. Because this is an autopsy study, the
esults may not adequately reflect the vascular responses of
iving patients who receive DES and BMS for treatment of
VBGs. Moreover, the small number of patients in this study
nd incomplete clinical data in some subjects did not permit an
ssessment of the contribution of deployment strategies that
ay have contributed to the pathological findings.
onclusions
The pathological characteristics of flow-limiting SVBG
ath, that demonstrates multiple stent struts (asterisk) penetrating into the
f the cross sections described in A and B (middle). The black box in each
yer of neointima (green arrow, bottom) is observed over the necrotic core.
reas of calciﬁcation (black arrow, bottom).ore de
tion o
hin laplaques are characterized by FA with large necrotic cores
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673and are frequently accompanied by plaque hemorrhage and
or a disrupted fibrous rupture. Stenting of these lesions,
regardless of stent type, often results in strut penetration of
the necrotic core. For DES, penetration of struts into
necrotic core contributes to increased delayed healing, likely
because of longer duration of drug retention resulting in
greater number of uncovered struts, which may contribute
to late thrombotic events. Treatment strategies that reduce
the lipid core burden within SVBGs warrant investigation
to improve outcomes post-DES implantation.
Reprint requests and correspondence: Dr. Renu Virmani, CV-
Path Institute Inc., 19 Firstfield Road, Gaithersburg, Maryland
20878. E-mail: rvirmani@cvpath.org.
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